Article

Bausch & Lomb offers aberration-free accommodating IOL with aspheric optics

Bausch & Lomb has announced the launch of the first aberration-free accommodating IOL with aspheric optics (Crystalens AO) to cataract surgeons worldwide.

Aliso Viejo, CA

-Bausch & Lomb has announced the launch of the first aberration-free accommodating IOL with aspheric optics (Crystalens AO) to cataract surgeons worldwide.

The lens has prolate aspheric surfaces and is designed to be free of spherical aberration, the company said in a prepared statement. The IOL is designed to improve retinal image quality without compromising depth of field and, therefore, it provides greater quality of distance and intermediate vision, according to a company statement.

“Some surgeons might assume because the Crystalens has aspheric optics, depth of field will be reduced. However, our comprehensive testing demonstrates the opposite to be true,” said Andy Corley, global president, Surgical, Bausch & Lomb. “Not all aspheric lenses are created the same, and other aspheric IOLs have negative spherical aberration, which could reduce depth of field. The Crystalens AO has zero spherical aberration, and the combination of the Crystalens platform and AO optics work[s] together to enhance depth of field.”

“We know that many surgeons prefer aspheric lenses because they believe that they correct for spherical aberrations and provide better quality of vision,” said Amy Jacobs, director of global marketing for the Crystalens.

The aspheric optic lens is composed of proprietary biosil silicone and has a thin and uninterrupted barrier edge. It will be inserted using an injector (CI-28) in a controlled manner through an unenlarged phaco incision, a routine requirement in today’s cataract surgical procedure.

The worldwide launch of the IOL is expected to accelerate through the first quarter of 2010, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.